Abstract
Pharmaceutical companies contribute over $13,000 per physician for promotion and advertisement of products. Psychiatrists and psychiatric residents are influenced by these interactions. Two recommendations to psychiatric residency training programs are offered: Incorporation of ethics education into teaching forums and the establishment of specific ground rules that would govern the interaction of pharmaceutical companies with psychiatric residents.
This is a preview of subscription content, log in via an institution to check access.
References
Heber A: Drug companies and doctors:a troubling alliance. Psychiatric Residency Newsletter 1993; 17:1–2
Hodges B: Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Can Med Assoc J 1995; 153:553–559
Lexchin J: Interactions between physicians and the pharmaceutical industry: what does the literature say? Can Med Assoc J 1993; 149:1401–1407
Lurie N, Rich EC, Simpson DE, et al: Pharmaceutical representatives in academic medical centers: interactions with faculty and housestaff. J Gen Intern Med 1990; 5:240–243
American Medical Association, Council on Ethical and Judicial Affairs of the American Medical Association: Gifts to Physicians From Industry. Chicago, IL, American Medical Association, 1997, pp 117–119
Johnstone RE, Valenzuela RC, Sullivan D: Managing pharmaceutical sales activities in an academic anesthesiology department. J Clin Anesthesia 1995; 7:544–548
Lichstein PR, Turner RC, O’Brien KO: Impact of pharmaceutical company representaives on internal medicine residency programs: a survey of residency program directors. Arch Intern Med 1992; 152:1009–1013
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Christensen, R.C., Tueth, M.J. Pharmaceutical Companies and Academic Departments of Psychiatry. Acad Psychiatry 22, 135–137 (1998). https://doi.org/10.1007/BF03341915
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03341915